Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mizuho Medy CoTSE:4595 -1.31%84 5-Year Yield-on-Cost % is 50.96 as of Aug. 03, 2026, which is 160% above its 10-year median of 19.58. GuruFocus rates TSE:4595 with a GF Score™ of 84/100 and a GF Value™ of 円1,432.86 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 514 Drug Manufacturers companies, Mizuho Medy Co ranks better than 97.86% on this metric.
Mizuho Medy Co's yield on cost for the quarter that ended in Dec. 2025 was 50.96.
The historical rank and industry rank for Mizuho Medy Co's 5-Year Yield-on-Cost % or its related term are showing as below:
TSE:4595'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.22 Med: 19.58 Max: 103.54
Current: 50.96
During the past 12 years, Mizuho Medy Co's highest Yield on Cost was 103.54. The lowest was 2.22. And the median was 19.58.
TSE:4595's 5-Year Yield-on-Cost % is ranked better than 97.86% of 514
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs TSE:4595: 50.96
Mizuho Medy Co (TSE:4595) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Mizuho Medy Co 5-Year Yield-on-Cost % Related Terms
TSE:4595 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mizuho Medy Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Mizuho Medy Co's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Mizuho Medy Co is calculated as
Mizuho Medy Co (TSE:4595) has a 5-Year Yield-on-Cost % of 50.96 as of Aug. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Mizuho Medy Co and its competitors. This is 160% above median its historical median of 19.58. Over the past decade, Mizuho Medy Co's 5-Year Yield-on-Cost % has ranged from 2.22 to 103.54. According to the industry distribution chart, Mizuho Medy Co ranks #11 out of 514 companies in the Drug Manufacturers industry, placing it in the top 2.1%.
Is Mizuho Medy Co's 5-Year Yield-on-Cost % too high?
Mizuho Medy Co's current 5-Year Yield-on-Cost % of 50.96 is 160% above median its 10-year median of 19.58. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 103.54. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Mizuho Medy Co's value of 50.96 is 2096.6% above this industry median. Based on the distribution chart, Mizuho Medy Co ranks #11 out of 514 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mizuho Medy Co has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mizuho Medy Co's 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mizuho Medy Co ranks #11 out of 514 companies for 5-Year Yield-on-Cost %. This places Mizuho Medy Co in the top 2% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.32. Mizuho Medy Co's value of 50.96 is 2096.6% above this benchmark. Historically, Mizuho Medy Co's own 5-Year Yield-on-Cost % has ranged from 2.22 to 103.54 over the past decade. While the company's 10-year median is 19.58 vs. the industry median of 2.32, Mizuho Medy Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mizuho Medy Co's current 5-Year Yield-on-Cost % of 50.96 is 2096.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Mizuho Medy Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mizuho Medy Co's current 5-Year Yield-on-Cost % is 50.96, which is 160% above median its own 10-year median of 19.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mizuho Medy Co stock overvalued right now?
Based on GuruFocus' analysis, Mizuho Medy Co (TSE:4595) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,432.86, compared to a current price of 円1,655.00 — trading 15.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 50.96, which is 160% above median its 10-year median of 19.58 and 2096.6% above the Drug Manufacturers industry median of 2.32. Mizuho Medy Co's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Mizuho Medy Co (TSE:4595), the current 5-Year Yield-on-Cost % is 50.96 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mizuho Medy Co (TSE:4595) Overvalued in 2026?
Based on GuruFocus' analysis, Mizuho Medy Co stock appears to be overvalued.
The current stock price of 円1,655.00 is trading 15.5% above its estimated GF Value™ of 円1,432.86.
GuruFocus considers Mizuho Medy Co to be Modestly Overvalued.
Key valuation signals for TSE:4595:
5-Year Yield-on-Cost %: 50.96 (160% above median its 10-year median of 19.58)
GF Value™: 円1,432.86 vs. price of 円1,655.00 (15.5% above fair value)
Industry Position: 2096.6% above the Drug Manufacturers median (#11 of 514)
No single metric tells the full story. See the TSE:4595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mizuho Medy Co Ltd engages in research and development, manufacture, and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including a digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.
84GF Score
Get the complete analysis for TSE:4595
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4595 has been successfully added to your 
